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Abstract: Introduction: Most of the headache cases only require pain management in emergency department (ED). The
present study aimed to evaluate the efficacy of intranasal lidocaine in this regard. Methods: In this clinical trial,
adult patients with primary headache were randomly treated with 7.5 mg intravenous (IV) chlorpromazine and
1 ml intranasal lidocaine 2% (treatment) or normal saline 0.9% (placebo), and were compared 5, 15, and 30
minutes later regarding success rate using SPSS 21. Results: 100 patients were assigned to either treatment or
placebo group. Number needed to treat of intranasal lidocaine at 5, 15, and 30 minutes were 4 (95% CI: 2.2 –
6.6), 3 (95% CI: 1.7 – 3.5), and 4 (95% CI: 2.3 – 15.9), respectively. These measures for absolute risk reduction
were 30 (95% CI: 15.2 – 44.8), 44 (95% CI: 28.7 – 59.3), and 26 percent (95% CI: 6.3 – 44.3), respectively. Pain
relapse occurred in 16% of treatment and 11% of control group within 1 hour of treatment (p = 0.402). Conclu-
sion: It seems that, intranasal lidocaine along with IV chlorpromazine could result in more successful and faster
management of primary headaches in ED.
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1. Introduction
H
eadache is a common cause of emergency depart-
ment (ED) visits. Most of these patients only require
symptomatic treatment and referral to a neurolo-
gist or the patient’s family physician on an outpatient basis
(1). Migraine, tension, and cluster are three types of primary
headaches with considerable clinical overlap, which suggests
the same pathophysiology (1).
Common drugs used to treat these headaches are intra-
venous (IV) and oral opioids, ergot alkaloids, antiemetic, and
non-steroidal anti-inflammatory drugs (NSAIDS) (2, 3). In-
tranasal route of drug administration may be more effec-
tive than other routes, with lower chance of emesis, and a
quicker onset of action (3). Intranasal delivery of zolmitrip-
tan, civamide, cocaine, and sumatriptan has been tried for
treatment of migraine and cluster headaches (4-7).
Lawrence Robbins showed the safety of intranasal lidocaine
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as a an adjunctive medication in cluster headache control (8).
Studies have reported that nasal lidocaine decreased cluster
and migraine headaches within several seconds to 2 minutes
(9, 10). However, Blanda and their colleagues didn’t find any
evidence that supports the mentioned issue (11).
There has been limited experiences regarding primary
headache management through intranasal medication in
ED. Therefore, this study aimed to evaluate the efficacy of in-
tranasal lidocaine in primary headache management in ED.
2. Methods
2.1. Study design and setting
This randomized, double blind placebo controlled trial was
done on patients presenting to emergency department of
Golestan Hospital, Ahwaz, Iran, from July 2012, to December
2014 with primary headache (migraine, cluster or tension).
The study design was approved by ethics committee of Ahvaz
Jundishapur University of Medical Sciences under the num-
ber U-91159 and registered on Iranian Registry of Clinical Tri-
als under this number: IRCT201212289148N2. Written in-
formed consent was obtained from all patients. Researchers
adhered to declaration of Helsinki protocol and confidential-
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Figure 1: Pain severity at the baseline and 5, 15, and 30 minutes af-
ter treatment in lidocaine and placebo groups based on visual ana-
logue scale (VAS).
ity of patients’ information.
2.2. Participants
The subjects were patients between 15 – 55 years old who
presented to the emergency department with complaints of
primary headaches (migraine, cluster, or tension) according
to the definition of International Headache Society and Ad
Hoc Committee on Classification of Headache. Patients with
signs of secondary headaches such as fever, meningismus,
trauma, unstable vital signs, and altered mental status were
excluded. Lactating and pregnant women as well as who had
taken analgesic medications 2 hours before referring to ED
were also excluded. Participants were randomly assigned to
either treatment or control group using simple random sam-
pling method.
2.3. Intervention
Patients in the treatment group received 1 mL intranasal li-
docaine 2% (20 mg lidocaine) and 7.5 mg intravenous (IV)
chlorpromazine and those in control group received 1 mL in-
tranasal normal saline 0.9% and 7.5 mg IV chlorpromazine.
The lidocaine and normal saline were sprayed with the same
shape and color containers.
2.4. Data gathering
A checklist that consisted of baseline characteristics (sex,
age), type of primary headache, pain severity, and possible
complications was filled for all patients by a senior emer-
gency medicine resident under supervision of an emergency
medicine physician. Visual analog scale (VAS) was used to
rate the pain severity at the baseline as well as 5, 15, and
30 minutes after drug administration. In addition, patients
were observed for an additional 30 minutes to assess whether
they responded to the treatment or whether their pain re-
turned. Patients, in charge physicians, and data analyzer
were blinded to drugs given to each group.
2.5. Outcome
5, 15, and 30 minute success rates were considered as the
main outcome of the study.
2.6. Statistical Analysis
Considering 95% confidence interval (CI), 80% power, and
according to the Maizals et al. and Blanda et al. findings (11,
12), the minimum sample size for each study group was cal-
culated to be 50 cases. Data analysis (intention to treat anal-
ysis) was performed by the statistical package for social sci-
ences (SPSS) version 21. Findings were presented as mean ±
standard deviation or frequency and percentage. Student t
test, ANOVA and chi square or Fisher’s exact tests were used
for comparisons. Success was defined as an at least 3 points
decrease of pain severity (based on VAS) 5, 15, or 30 minutes
after treatment. P < 0.05 was considered as significant.
3. Results
3.1. Baseline characteristics
100 patients were randomly assigned to either treatment (50
cases) or control (50 cases) group (54.0% female). The mean
age of treatment and control groups were 32.96 ± 8.51 and
29.60 ± 8.64 years, respectively (p = 0.050). Table 1 shows the
baseline characteristics of studied patients.
3.2. Pain control
The mean pain severity of patients at the time of present-
ing to emergency department and 5, 15, and 30 minutes after
treatment are summarized in table 2 and figure 1.
The success rates of two groups at 5, 15, and 30 minutes are
compared in table 3. There was not any significant correla-
tion between success rate and sex (p = 0.292), age (p = 0.380),
and type of headache (p = 0.489).
Number needed to treat of intranasal lidocaine at 5, 15, and
30 minutes were 4 (95% CI: 2.2 – 6.6), 3 (95% CI: 1.7 – 3.5), and
4 (95% CI: 2.3 – 15.9), respectively. These measures for abso-
lute risk reduction were 30 (95% CI: 15.2 – 44.8), 44 (95% CI:
28.7 – 59.3), and 26 percent (95% CI: 6.3 – 44.3), respectively.
The side effects related to treatment were not apparent in ei-
ther the treatment or the control group within 30 minutes af-
ter treatment. Pain relapse occurred in 16% of the treatment
and 11% of the control group during 1 hour follow up (p =
0.402).
4. Discussion
Considering 30, 44, and 26 percent absolute risk reduction
at 5, 15, and 30 minutes after treatment, intranasal lidocaine
along with intravenous chlorpromazine could result in more
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Male 22 (44.0) 24 (48.0)
0.688
Female 28(56.0) 26 (52.0)
Age (year)
20 – 29.9 20 (40.0) 31 (62.0)
30 – 39.9 10 (20.0) 10 (20.0) 0.038
≥ 40 20 (40.0) 9 (18.0)
Type of headache
Migraine 16 (32.0) 22 (44.0)
Tension 11 (22.0) 18 (36.0) 0.028
Cluster 23 (46.0) 10 (20.0)





Baseline 6.15 ± 1.19 5.87 ± 1.01 0.225
5 4.56 ± 1.54 5.30 ± 1.29 0.011
15 3.86 ± 1.57 4.76 ± 1.09 0.001
30 2.94 ± 1.63 3.94 ± 1.52 0.002





5 18 (36) 3 (6) < 0.0001
15 25 (50) 3 (6) < 0.0001
30 30 (60) 17 (34) 0.009
successful pain management of primary headaches in ED.
This study showed that patients who received intranasal li-
docaine along with IV chlorpromazine significantly experi-
enced higher success rate in pain control at 5, 15, and 30 min-
utes after treatment.
Although the two studied groups had different baseline char-
acteristics, the analysis of data didn’t show any relationship
between age, sex, and type of primary headache with treat-
ment success rate.
Maizels and Geiger evaluated the efficacy of intranasal li-
docaine in a double-blind controlled trial with open-label
follow-up. They found that headache was relieved within 15
min in 35.8% of patients in the treatment group, with a 20.6%
relapse rate (12). Mohammadkarimi and colleagues using in-
tranasal lidocaine in 90 patients with primary and secondary
headaches found significant pain relief after 1 minute, and
showed that the level of patients’ pain did not significantly
change over the course of the study. They did not assess the
relapse rates or side effects related to treatment (9). In con-
trast, Blanda and colleagues found that the intranasal lido-
caine did not relieve pain after 5 or 30 minutes (11).
Although the experience of drug delivery through nasal mu-
cosa goes back to many years ago, based on a review in 2013
the present method for delivering the drug to the posterior-
superior part of the nose is not that effective and this could
affect the success rate of this method to a great extent (13).
It seems that using a new method that can be applied by the
patients themselves without the need for visiting the hospi-
tal should be considered more seriously. This is of great im-
portance, especially for cases such as primary headaches that
are usually recurrent and distractive. Of course, there is still
a long way to go in making the use of these drugs public and
revising traditional methods.
5. Limitation
In the current study, we administered intranasal 2% lidocaine
for different types of headache and not just for migraine. We
followed patients in both the treatment and control groups
for only a short time. We did not perform follow-up assess-
ments. In addition, because our treatment group received
lidocaine and chlorpromazine together, our study is limited
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in its assessment of pure lidocaine’s ability in pain manage-
ment.
6. Conclusion
Considering 30, 44, and 26 percent absolute risk reduction
at 5, 15, and 30 minutes after treatment, intranasal lidocaine
along with IV chlorpromazine could result in more successful
and faster management of primary headaches in ED.
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